PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
Author:
Affiliation:
1. Research & Development, Pharmaceuticals Bayer AG Wuppertal/Berlin Germany
2. Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P) Leiden The Netherlands
3. Ionis Pharmaceuticals, Inc Carlsbad California USA
Publisher
Wiley
Subject
Pharmacology (medical),Modeling and Simulation
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12663
Reference22 articles.
1. Factors XI and XII as Targets for New Anticoagulants
2. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
3. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis
4. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events
5. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Factor XIa inhibition as a therapeutic strategy for atherothrombosis;Journal of Thrombosis and Thrombolysis;2024-07-29
2. Therapeutic Potential of FXI Inhibitors: Hype or Hope?;Drugs;2024-07-29
3. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis;Kidney International;2024-07
4. The current landscape of factor XI inhibitors;Thrombosis Update;2024-06
5. Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor;CPT: Pharmacometrics & Systems Pharmacology;2024-05-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3